WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. ("Eagle") (Nasdaq:EGRX) today announced that the Company will release its 2014 third quarter financial results on Monday, August 11, 2014, before the market opens. Following release of the results, the Company will host a conference call at 8:30 a.m. Eastern Daylight Time. Scott Tar […]
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced today that it will report its second 2014 financial results on Wednesday, August 6, 2014 at approximately 4:30 p.m. ET. The press release will be followed by a conference call and webcast at 5:00 p.m. ET. To participate in the conference call, dial (800) 510-9691 and use pas […]
MORRISTOWN, N.J.--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2014 financial results before the U.S. stock market opens on Monday, August 11, 2014 and has scheduled a conference call at 10:00 a.m. EDT that day to discuss the financial results. T […]
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announces that Edward J. Quilty, its chief executive officer, delivered a presentation highlighting MEDIHONEY® and its robust growth at the Comvita Ltd. annual meetings of shareholders in New Zealand on Thursday, July 24. During […]
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent.
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) reported net product sales of $1,845 million for the second quarter of 2014, an 18 percent increase from the same period in 2013. Second quarter total revenue increased 17 percent to $1,873 million compared to $1,599 million in the second quarter of 2013. Adjusted net income for the second quar […]
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that it has received a No Objection Letter (“NOL”) from Health Ca […]